Skip to Content

How does Zinbryta work?

Medically reviewed by Last updated on Sep 10, 2019.

Official Answer


Zinbryta is thought to work by decreasing T-cells and pro-inflammatory lymphoid tissue inducer cells, and increasing CD56bright natural killer (NK) cells, important cells that help regulate the immune system.

In studies, patients using Zinbryta had fewer clinical relapses than patients taking placebo or another multiple sclerosis (MS) treatment Avonex (interferon beta-1a).

In May 2016, the FDA approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis (MS).

In March 2018, Biogen and AbbVie announced the voluntary worldwide withdrawal of Zinbryta for relapsing multiple sclerosis.

Related Medical Questions

Drug Information

Related Support Groups